Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Affimed N.V. (AFMD) has received a deficiency notice from Nasdaq dated April 15, 2025, due to its stock price closing below the minimum requirement of $1.00 per share for the last 30 consecutive business days. The company has been granted an initial 180-day period until October 13, 2025, to regain compliance with the minimum bid price requirement.
If compliance is not achieved during this period, Affimed may consider transferring from The Nasdaq Global Select Market to The Nasdaq Capital Market, which could provide an additional 180 days (until April 13, 2025) to meet requirements. This transfer would be subject to meeting other listing criteria. The notice does not immediately affect the listing or trading of Affimed's shares.
Affimed N.V. (AFMD) ha ricevuto un avviso di non conformità da Nasdaq datato 15 aprile 2025, a causa del prezzo delle sue azioni che ha chiuso sotto il requisito minimo di $1,00 per azione negli ultimi 30 giorni lavorativi consecutivi. Alla società è stato concesso un periodo iniziale di 180 giorni, fino al 13 ottobre 2025, per tornare a rispettare il requisito minimo del prezzo di offerta.
Se il rispetto non verrà raggiunto entro questo periodo, Affimed potrebbe prendere in considerazione il trasferimento dal Nasdaq Global Select Market al Nasdaq Capital Market, che potrebbe offrire ulteriori 180 giorni (fino al 13 aprile 2026) per soddisfare i requisiti. Questo trasferimento sarebbe soggetto al rispetto di altri criteri di quotazione. L’avviso non influisce immediatamente sulla quotazione o sulla negoziazione delle azioni di Affimed.
Affimed N.V. (AFMD) ha recibido un aviso de deficiencia por parte de Nasdaq con fecha 15 de abril de 2025, debido a que el precio de sus acciones cerró por debajo del requisito mínimo de $1.00 por acción durante los últimos 30 días hábiles consecutivos. A la empresa se le ha otorgado un período inicial de 180 días hasta el 13 de octubre de 2025 para recuperar el cumplimiento del requisito mínimo del precio de oferta.
Si no se logra el cumplimiento durante este período, Affimed podría considerar transferirse del Nasdaq Global Select Market al Nasdaq Capital Market, lo que podría proporcionar un plazo adicional de 180 días (hasta el 13 de abril de 2026) para cumplir con los requisitos. Esta transferencia estaría sujeta a cumplir otros criterios de listado. El aviso no afecta de inmediato la cotización ni la negociación de las acciones de Affimed.
Affimed N.V. (AFMD)는 2025년 4월 15일자 나스닥으로부터 주가가 지난 30거래일 연속으로 주당 $1.00 미만으로 마감했다는 이유로 결격 통보를 받았습니다. 회사는 2025년 10월 13일까지 180일의 초기 기간 동안 최저 입찰가 요건을 충족하도록 허용받았습니다.
이 기간 내에 요건을 충족하지 못할 경우, Affimed는 나스닥 글로벌 셀렉트 마켓에서 나스닥 캐피털 마켓으로 이전하는 방안을 고려할 수 있으며, 이 경우 추가로 180일(2026년 4월 13일까지)의 기간이 주어져 요건 충족이 가능할 수 있습니다. 이 이전은 다른 상장 기준 충족을 조건으로 합니다. 이 통보는 Affimed 주식의 상장이나 거래에 즉각적인 영향을 미치지 않습니다.
Affimed N.V. (AFMD) a reçu un avis de non-conformité de la part du Nasdaq daté du 15 avril 2025, en raison du cours de son action qui a clôturé en dessous du seuil minimum de 1,00 $ par action pendant les 30 jours ouvrables consécutifs précédents. La société bénéficie d’une période initiale de 180 jours, jusqu’au 13 octobre 2025, pour se conformer à l’exigence minimale du prix d’offre.
Si la conformité n’est pas atteinte durant cette période, Affimed pourrait envisager un transfert du Nasdaq Global Select Market vers le Nasdaq Capital Market, ce qui pourrait accorder 180 jours supplémentaires (jusqu’au 13 avril 2026) pour respecter les exigences. Ce transfert serait soumis au respect d’autres critères de cotation. Cet avis n’affecte pas immédiatement la cotation ou la négociation des actions d’Affimed.
Affimed N.V. (AFMD) hat am 15. April 2025 von der Nasdaq eine Mängelmitteilung erhalten, da der Aktienkurs an den letzten 30 aufeinanderfolgenden Handelstagen unter der Mindestanforderung von 1,00 USD pro Aktie schloss. Dem Unternehmen wurde eine anfängliche Frist von 180 Tagen bis zum 13. Oktober 2025 eingeräumt, um die Einhaltung der Mindestgebotspreis-Anforderung wiederherzustellen.
Wenn die Einhaltung innerhalb dieses Zeitraums nicht erreicht wird, könnte Affimed erwägen, vom Nasdaq Global Select Market zum Nasdaq Capital Market zu wechseln, was eine zusätzliche Frist von 180 Tagen (bis zum 13. April 2026) zur Erfüllung der Anforderungen bieten könnte. Dieser Wechsel wäre an weitere Zulassungskriterien gebunden. Die Mitteilung hat keine unmittelbaren Auswirkungen auf die Notierung oder den Handel der Affimed-Aktien.
- 180-day grace period granted to regain compliance
- Possibility of additional 180-day extension if eligible for Nasdaq Capital Market transfer
- Company maintains Nasdaq listing status during compliance period
- Stock price has fallen below $1.00 for 30 consecutive business days
- Risk of potential delisting from Nasdaq if compliance is not achieved
- May need to transfer to Nasdaq Capital Market, typically considered a lower-tier exchange
Insights
Nasdaq deficiency notice threatens Affimed's listing status, requiring action to raise share price above $1 before potential delisting.
Affimed's receipt of a Nasdaq deficiency notice represents a significant regulatory challenge with potential implications for shareholders. The notice, triggered after 30 consecutive business days of trading below the $1.00 minimum threshold, initiates a defined compliance timeline that requires immediate attention.
The company now faces a 180-day compliance window until October 13, 2025 to meet the minimum bid price requirement. To regain compliance, Affimed must achieve a closing bid price of at least $1.00 for a minimum of 10 consecutive business days during this period.
If unsuccessful, Affimed may pursue a transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market, potentially securing an additional 180-day grace period until April 13, 2025 - contingent on meeting other listing requirements. However, this secondary pathway is not guaranteed, as the company would need to satisfy applicable market value requirements and secure Nasdaq approval.
Companies in this situation typically consider several options: pursuing value-creating business developments that naturally increase share price, implementing a reverse stock split to artificially elevate the share price, or transferring to a different exchange with less stringent requirements.
While the notice has no immediate effect on stock trading, it creates pressure to address the underlying market performance issues. For clinical-stage biotechs like Affimed, with
The ultimate risk of non-compliance is delisting, which would severely impact trading liquidity, institutional investor access, and potentially trigger violations in financing agreements. This notice essentially starts a countdown clock for Affimed to either demonstrate improved market performance or implement corporate actions to address the price deficiency.
MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed below the minimum
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 13, 2025, to regain compliance. If the Company fails to regain compliance with the Minimum Bid Price Rule during this period, the Company may consider applying to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market, provided that the Company meets the applicable market value of publicly held shares required for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement). Such transfer would provide the Company with an additional 180 calendar days, or until April 13, 2025, to regain compliance. There can be no assurance that the Company would be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company’s request for continued listing.
The Notice has no immediate effect on the listing or trading of the Company’s common shares.
The Company intends to monitor the bid price of its common shares and consider available options to regain compliance with the Minimum Bid Price Rule.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements include, among other things, statements regarding the Company’s compliance with the Minimum Bid Price Rule and listing or trading of the Company’s common shares. Actual results may differ materially from the results anticipated by the Company’s forward-looking statements due to certain risks, uncertainties and other factors described under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Investor Relations Contact
Alexander Fudukidis
Director, Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin
Vice President, Marketing and Communications
E-Mail: m.sandin@affimed.com
FAQ
What happens if AFMD stock stays below $1 after the initial 180-day compliance period?
When does AFMD need to regain compliance with Nasdaq's minimum bid price requirement?
Will AFMD be immediately delisted from Nasdaq due to the deficiency notice?
What is the minimum stock price AFMD needs to maintain for Nasdaq compliance?
